Last quarter (Q4 2023), Connect Biopharma Holdings's total revenue was ¥―, a decrease of ― from the same quarter last year. In Q4, Connect Biopharma Holdings's net income was ¥―. See Connect Biopharma Holdings’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	-	-	-	-	¥ 0.00	¥ 0.00
Cost of Revenue	-	-	¥ -7.99M	¥ -13.72M	-	-
Gross Profit	-	-	¥ 7.99M	¥ 13.72M	-	-
Operating Expense	-	¥ 66.43M	¥ 101.23M	¥ 110.46M	¥ 191.66M	¥ 113.29M
Operating Income	-	¥ -66.43M	¥ -101.23M	¥ -110.46M	¥ -191.66M	¥ -113.29M
Net Non Operating Interest Income Expense	-	¥ 2.59M	¥ 10.71M	¥ 98.00K	¥ -2.18M	¥ 1.01M
Other Income Expense	-	¥ -4.09M	¥ -924.00K	¥ 102.78M	¥ -585.39M	¥ -56.35M
Pretax Income	-	¥ -59.38M	¥ -795.02M	¥ -213.14M	¥ -779.23M	¥ -168.63M
Tax Provision	-	¥ 120.00K	¥ 2.00M	¥ 1.70M	¥ 0.00	¥ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	¥ -59.50M	¥ -124.55M	¥ -214.84M	¥ -779.23M	¥ -168.63M
Basic EPS	-	¥ -1.08	¥ -14.50	¥ -25.00	¥ -13.96	¥ -3.02
Diluted EPS	-	¥ -1.08	¥ -2.10	-	¥ -13.96	¥ -3.02
Basic Average Shares	-	¥ 55.07M	¥ 55.04M	¥ 52.18M	¥ 55.82M	¥ 55.82M
Diluted Average Shares	-	¥ 55.07M	¥ 59.31M	-	¥ 55.82M	¥ 55.82M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	-	¥ 66.43M	¥ 93.25M	¥ 96.75M	¥ 191.66M	¥ 113.29M
Net Income From Continuing And Discontinued Operation	-	¥ -59.50M	¥ -124.55M	¥ -214.84M	¥ -779.23M	¥ -168.63M
Normalized Income	-	¥ -43.65M	-	-	¥ -773.13M	¥ -171.68M
Interest Expense	-	-	-	-	¥ 42.00K	¥ 53.00K
EBIT	-	¥ -59.36M	¥ -795.16M	¥ -213.24M	¥ -779.18M	¥ -168.57M
EBITDA	-	¥ -58.37M	¥ -802.10M	¥ -217.32M	¥ -777.74M	¥ -167.78M

Currency in CNY

Connect Biopharma Holdings Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing